Estrogen receptor β and the progression of prostate cancer: Role of 5α-androstane-3β,17β-diol

Endocrine-Related Cancer

Volumn 17, Issue 3, 2010, Pages 731-742

  Dondi, Donatella ^a   Piccolella, Margherita ^a   Biserni, Andrea ^a   Torre, Sara Della ^a   Ramachandran, Balaji ^a   Locatelli, Alessia ^a   Rusmini, Paola ^a   Sau, Daniela ^a   Caruso, Donatella ^a   Maggi, Adriana ^a   Ciana, Paolo ^a   Poletti, Angelo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA ANDROSTANEDIOL; ESTRADIOL; ESTROGEN RECEPTOR BETA; FULVESTRANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INVASION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NONHUMAN; PROSTATE CANCER; TUMOR XENOGRAFT;

ANABOLIC AGENTS; ANDROSTANE-3,17-DIOL; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN; DRUG COMBINATIONS; ESTROGEN RECEPTOR BETA; HUMANS; LAMININ; MALE; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTEOGLYCANS; RECEPTORS, ANDROGEN; SURVIVAL RATE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956382505     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-10-0032     Document Type: Article

References (50)

1. Arnold JT, Liu X, Allen JD, Le H, McFann KK & Blackman MR 2007 Androgen receptor or estrogen receptor-β blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. Prostate 67 1152-1162.
2. Balk SP 2002 Androgen receptor as a target in androgenin-dependent prostate cancer. Urology 60 132-138.
3. Bauman DR, Steckelbroeck S, Peehl DM & Penning TM 2006 Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer. Endocrinology 147 5806-5816. (Pubitemid 44833497)
4. Beuten J, Gelfond JA, Franke JL, Weldon KS, Crandall AC, Johnson-Pais TL, Thompson IM & Leach RJ 2009 Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiology, Biomarkers and Prevention 18 1869-1880.
5. Bonaccorsi L, Muratori M, Carloni V, Zecchi S, Formigli L, Forti G & Baldi E 2003 Androgen receptor and prostate cancer invasion. International Journal of Andrology 26 21-25. (Pubitemid 36110851)
6. Buijs JT, Rentsch CA, van der Horst G, van Overveld PG, Wetterwald A, Schwaninger R, Henriquez NV, Ten Dijke P, Borovecki F, Markwalder R et al. 2007 BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. American Journal of Pathology 171 1047-1057.
7. Caruso D, Scurati S, Maschi O, De Angelis L, Roglio I, Giatti S, Garcia-Segura LM & Melcangi RC 2008 Evaluation of neuroactive steroid levels by liquid chromatography-tandem mass spectrometry in central and peripheral nervous system: effect of diabetes. Neurochemistry International 52 560-568.
8. Chang BL, Zheng SL, Hawkins GA, Isaacs SD, Wiley KE, Turner A, Carpten JD, Bleecker ER, Walsh PC, Trent JM et al. 2002 Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. Cancer Research 62 1784-1789.
9. Cheng J, Lee EJ, Madison LD & Lazennec G 2004 Expression of estrogen receptor β in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Letters 566 169-172. (Pubitemid 38625953)
10. Ciana P, Raviscioni M, Mussi P, Vegeto E, Que I, Parker MG, Lowik C & Maggi A 2003 In vivo imaging of transcriptionally active estrogen receptors. Nature Medicine 9 82-86.
11. Ciana P, Brena A, Sparaciari P, Bonetti E, Di Lorenzo D & Maggi A 2005 Estrogenic activities in rodent estrogen-free diets. Endocrinology 146 5144-5150. (Pubitemid 41653028)
12. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ & Sugimura Y 1987 The endocrinology and developmental biology of the prostate. Endocrine Reviews 8 338-362.
13. Cunningham JM, Hebbring SJ, McDonnell SK, Cicek MS, Christensen GB, Wang L, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ et al. 2007 Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiology, Biomarkers and Prevention 16 969-978. (Pubitemid 46910099)
14. Freedland SJ, Eastham J & Shore N 2009 Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. Prostate Cancer and Prostatic Diseases 12 333-338.
15. Guerini V, Sau D, Scaccianoce E, Rusmini P, Ciana P, Maggi A, Martini PG, Katzenellenbogen BS, Martini L, Motta M et al. 2005 The androgen derivative 5α-androstane-3β,17β-diol inhibits prostate cancer cell migration through activation of the estrogen receptor β subtype. Cancer Research 65 5445-5453. (Pubitemid 40827358)
16. Gustafsson JA 2003 What pharmacologists can learn from recent advances in estrogen signalling. Trends in Pharmacological Sciences 24 479-485.
17. Imamov O, Lopatkin NA & Gustafsson JA 2004 Estrogen receptor β in prostate cancer. New England Journal of Medicine 351 2773-2774.
18. Koehler KF, Helguero LA, Haldosen LA, Warner M & Gustafsson JA 2005 Reflections on the discovery and significance of estrogen receptor b. Endocrine Reviews 26 465-478. (Pubitemid 40691301)
19. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S & Gustafsson JA 1996 Cloning of a novel estrogen receptor expressed in rat prostate and ovary. PNAS 93 5925-5930.
20. Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S & Gustafsson JA 1997 Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors and b. Endocrinology 138 863-870. (Pubitemid 27089735)
21. Kuiper GGJM, Shughrue PJ, Merchenthaler I & Gustafsson JA 1998 The estrogen receptor β subtype: a novel mediator of estrogen action in neuroendocrine systems. Frontiers in Neuroendocrinology 19 253-286.
22. Lazennec G, Bresson D, Lucas A, Chauveau C & Vignon F 2001 ERβ inhibits proliferation and invasion of breast cancer cells. Endocrinology 142 4120-4130. (Pubitemid 32802685)
23. Marron TU, Guerini V, Rusmini P, Sau D, Brevini TAL, Martini L & Poletti A 2005 Androgen-induced neurite outgrowth is mediated by neuritin in motor neurones. Journal of Neurochemistry 92 10-20. (Pubitemid 40193505)
24. Matsushima H, Goto T, Hosaka Y, Kitamura T & Kawabe K 1999 Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation. Cancer 85 1822-1827. (Pubitemid 29169685)
25. Matthews J & Gustafsson JA 2003 Estrogen signaling: a subtle balance between ERα and ERβ. Molecular Interventions 3 281-292.
26. Mindnich RD & Penning TM 2009 Aldo-keto reductase (AKR) superfamily: genomics and annotation. Human Genomics 3 362-370.
27. Neslund-Dudas C, Bock CH, Monaghan K, Nock NL, Yang JJ, Rundle A, Tang D & Rybicki BA 2007 SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness. Prostate 67 1654-1663.
28. Neubauer BL, McNulty AM, Chedid M, Chen K, Goode RL, Johnson MA, Jones CD, Krishnan V, Lynch R, Osborne HE et al. 2003 The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model. Cancer Research 63 6056-6062.
29. Nilsson S, Mäkelä S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M & Gustafsson JA 2001 Mechanisms of estrogen action. Physiological Reviews 81 1535-1565.
30. Normington K & Russell DW 1992 Tissue distribution and kinetic characteristics of rat steroid 5α-reductase isozymes. Evidence for distinct physiological functions. Journal of Biological Chemistry 267 19548-19554.
31. Park JY, Tanner JP, Sellers TA, Huang Y, Stevens CK, Dossett N, Shankar RA, Zachariah B, Heysek R & Pow-Sang J 2007 Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk. Urology 70 374-379.
32. Pesaresi M, Maschi O, Giatti S, Garcia-Segura LM, Caruso D & Melcangi RC 2010 Sex differences in neuroactive steroid levels in the nervous system of diabetic and non-diabetic rats. Hormones and Behavior 57 46-55.
33. Poletti A & Martini L 1999 Androgen-activating enzymes in the central nervous system. Journal of Steroid Biochemistry and Molecular Biology 69 117-122. (Pubitemid 29305529)
34. Poletti A, Negri-Cesi P, Melcangi RC, Colciago A, Martini L & Celotti F 1997 Expression of androgen-activating enzymes in cultured cells of developing rat brain. Journal of Neurochemistry 68 1298-1303. (Pubitemid 27086236)
35. Poletti A, Rampoldi A, Piccioni F, Volpi S, Simeoni S, Zanisi M & Martini L 2001 5α-reductase type 2 and androgen receptor expression in gonadotropin releasing hormone GT1-1 cells. Journal of Neuroendocrinology 13 353-357. (Pubitemid 32237008)
36. Poletti A, Negri-Cesi P & Martini L 2005 Reflections on the diseases linked to mutations of the androgen receptor. Endocrine 28 243-262.
37. Pozzi P, Bendotti C, Simeoni S, Piccioni F, Guerini V, Marron TU, Martini L & Poletti A 2003 Androgen 5-α-reductase type 2 is highly expressed and active in rat spinal cord motor neurones. Journal of Neuroendocrinology 15 882-887. (Pubitemid 37038614)
38. Roselli CE & Resko JA 1993 Aromatase activity in the rat brain: hormonal regulation and sex differences. Journal of Steroid Biochemistry and Molecular Biology 44 499-508. (Pubitemid 23126621)
39. Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW & Freedman M 2008 Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. Journal of Clinical Oncology 26 842-847. (Pubitemid 351398074)
40. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG & Balk SP 2006 Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Research 66 2815-2825.
41. Steckelbroeck S, Jin Y, Gopishetty S, Oyesanmi B & Penning TM 2004 Human cytosolic 3α-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3β-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action. Journal of Biological Chemistry 279 10784-10795. (Pubitemid 38379543)
42. Stell A, Biserni A, Della Torre S, Rando G, Ramachandran B, Ottobrini L, Lucignani G, Maggi A & Ciana P 2007 Cancer modeling: modern imaging applications in the generation of novel animal model systems to study cancer progression and therapy. International Journal of Biochemistry and Cell Biology 39 1288-1296. (Pubitemid 47031034)
43. Treeck O, Lattrich C, Springwald A & Ortmann O 2010 Estrogen receptor β exerts growth-inhibitory effects on human mammary epithelial cells. Breast Cancer Research and Treatment 120 557-565.
44. Warner M & Gustafsson JA 1995 Cytochrome P450 in the brain: neuroendocrine functions. Frontiers in Neuroendocrinology 16 224-236.
45. Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, Webster JI, Jensen EV, Nilsson S, Warner M & Gustafsson JA 2001 A role for estrogen receptor β in the regulation of growth of the ventral prostate. PNAS 98 6330-6335.
46. Weihua Z, Lathe R, Warner M & Gustafsson JA 2002a An endocrine pathway in the prostate, ERβ, AR, 5α-androstane-3β,17β- diol, and CYP7B1, regulates prostate growth. PNAS 99 13589-13594.
47. Weihua Z, Warner M & Gustafsson JA 2002b Estrogen receptor β in the prostate. Molecular and Cellular Endocrinology 193 1-5.
48. Weihua Z, Andersson S, Cheng G, Simpson ER, Warner M & Gustafsson JA 2003 Update on estrogen signaling. FEBS Letters 546 17-24.
49. Wilson JD, Griffin JE & Russell DW 1993 Steroid 5α-reductase 2 deficiency. Endocrine Reviews 14 577-593.
50. Zhu YS & Imperato-McGinley JL 2009 5α-reductase isozymes and androgen actions in the prostate. Annals of the New York Academy of Sciences 1155 43-56.